{"slideshow_credits": null, "snippet": "Missteps by Valeant, along with aggressive accounting practices and unusual business relationships, derailed one of the most intriguing drugs in a generation.", "abstract": "Future of Addyi, so-called 'female Viagra' approved by Food and Drug Admin to treat low sex drive in women, appears murky following manufacturer Valeant Pharmaceuticals' dismissal of product's entire sales force; drug firm has been besieged with internal problems and severe drop in stock price since it purchased Addyi's owner Sprout Pharmaceuticals for $1 billion in 2015.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Katie", "role": "reported", "lastname": "THOMAS", "rank": 1, "organization": ""}, {"firstname": "Gretchen", "role": "reported", "lastname": "MORGENSON", "rank": 2, "organization": ""}], "original": "By KATIE THOMAS and GRETCHEN MORGENSON"}, "web_url": "http://www.nytimes.com/2016/04/10/business/female-viagra-addyi-valeant-dysfunction.html", "lead_paragraph": "Missteps by Valeant, along with aggressive accounting practices and unusual business relationships, derailed one of the most intriguing drugs in a generation.", "headline": {"main": "The Female Viagra, Undone by a Drug Maker\u2019s Dysfunction", "print_headline": "What Went Wrong for \u2018Female Viagra\u2019"}, "_id": "57092d4b38f0d84b5a70611c", "word_count": "2104", "multimedia": [{"height": 126, "url": "images/2016/04/10/business/10SPROUT/10SPROUT-thumbWide-v2.jpg", "legacy": {"wideheight": "126", "wide": "images/2016/04/10/business/10SPROUT/10SPROUT-thumbWide-v2.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 330, "url": "images/2016/04/10/business/10SPROUT/10SPROUT-articleLarge-v2.jpg", "legacy": {"xlarge": "images/2016/04/10/business/10SPROUT/10SPROUT-articleLarge-v2.jpg", "xlargewidth": "600", "xlargeheight": "330"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2016/04/10/business/10SPROUT/10SPROUT-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/04/10/business/10SPROUT/10SPROUT-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2016-04-10T00:00:00Z", "source": "The New York Times", "news_desk": "SundayBusiness", "keywords": [{"name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Addyi (Drug)", "is_major": "Y", "rank": "2"}, {"name": "organizations", "value": "Sprout Pharmaceuticals Inc", "is_major": "N", "rank": "3"}, {"name": "organizations", "value": "Philidor Rx Services LLC", "is_major": "N", "rank": "4"}, {"name": "persons", "value": "Ackman, William A", "is_major": "N", "rank": "5"}], "blog": [], "subsection_name": null, "type_of_material": "News"}